TNF and infection: Evidence is emerging that antibody concentrations decrease more rapidly in patients with IBD treated with anti-TNF drugs and that these patients are at greater risk of breakthrough infection following two doses of vaccine than patients with IBD treated with vedolizumab.6, 7, 8